Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate
Version of Record online: 17 FEB 2005
British Journal of Clinical Pharmacology
Volume 59, Issue 5, pages 598–601, May 2005
How to Cite
Snell, P., Dave, N., Wilson, K., Rowell, L., Weil, A., Galitz, L. and Robson, R. (2005), Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. British Journal of Clinical Pharmacology, 59: 598–601. doi: 10.1111/j.1365-2125.2005.02340.x
- Issue online: 2 MAR 2005
- Version of Record online: 17 FEB 2005
- Received 8 March 2004 Accepted 6 October 2004
- 4FDA Draft: Guidance for Industry, November 1999: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling.
- 5Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64–0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatographr B Biomed Sci Appl 2000; 745: 373–88., , , et al.